These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26634944)

  • 1. The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.
    Waks AG; Tolaney SM
    Future Oncol; 2015; 11(24):3261-71. PubMed ID: 26634944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
    de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
    Burstein HJ
    Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers.
    Musolino A; Boggiani D; Sikokis A; Rimanti A; Pellegrino B; Vattiato R; Sgargi P; Falcini F; Caminiti C; Michiara M; Leonardi F
    Cancer Treat Rev; 2016 Feb; 43():1-7. PubMed ID: 26827687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
    Pernas S; Gil-Gil M; de Olza MO; Gumà A; Climent F; Petit A; Pla MJ; García-Tejedor A; López-Ojeda A; Falo C; Fernandez-Otega A; Mesia C; Pérez-Martin FJ; Urruticoechea A; Germà JR
    Breast Cancer Res Treat; 2012 Aug; 134(3):1161-8. PubMed ID: 22772380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Small HER2-positive breast cancer: which prognosis and which adjuvant treatment?].
    Gonçalves A; Vassilakopoulou M; Spano JP
    Bull Cancer; 2013 Sep; 100(9):847-56. PubMed ID: 23899689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of small HER2-positive breast cancers.
    Banerjee S; Smith IE
    Lancet Oncol; 2010 Dec; 11(12):1193-9. PubMed ID: 21126688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.
    Barroso-Sousa R; Exman P; Tolaney SM
    Future Oncol; 2018 Apr; 14(10):937-945. PubMed ID: 29589471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab in small tumours and in elderly women.
    Albanell J; Ciruelos EM; Lluch A; Muñoz M; Rodríguez CA
    Cancer Treat Rev; 2014 Feb; 40(1):41-7. PubMed ID: 23659993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
    Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
    Zardavas D; Fouad TM; Piccart M
    Breast; 2015 Nov; 24 Suppl 2():S143-8. PubMed ID: 26255196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
    Gori S; Inno A; Fiorio E; Foglietta J; Ferro A; Gulisano M; Pinotti G; Gubiotti M; Cavazzini MG; Turazza M; Duranti S; De Simone V; Iezzi L; Bisagni G; Spazzapan S; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Santini D; Fabi A; Garrone O; Frassoldati A; Amaducci L; Saracchini S; Evangelisti L; Barni S; Gamucci T; Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L
    PLoS One; 2015; 10(9):e0136731. PubMed ID: 26340098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
    Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM;
    Clin Breast Cancer; 2015 Feb; 15(1):31-6. PubMed ID: 25065563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients.
    Hacioglu B; Akin S; Sever AR; Altundag K
    Future Oncol; 2015 Sep; 11(18):2495-7. PubMed ID: 26278702
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?
    Paplomata E; Nahta R; O'Regan RM
    Cancer; 2015 Feb; 121(4):517-26. PubMed ID: 25346473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.